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Abstract
Background: Although the efficacy of bevacizumab has been established in patients with metastatic colorectal cancer
(mCRC), population-based studies are needed to gain insight into the actual implementation of bevacizumab in daily
practice. Since these studies are lacking for patients with metachronous metastases, the aim of this study is to evaluate
the current role of bevacizumab in the treatment of metachronous metastases of CRC.
Methods: Data on the use of bevacizumab as palliative treatment of metachronous metastases were collected for
patients diagnosed with M0 CRC between 2003 and 2008 in the Eindhoven Cancer Registry (n = 361). Median follow
up was 5.3 years.
Results: One hundred eighty-five patients received bevacizumab in addition to first-line palliative chemotherapy
(51 %), ranging from 36 % to 80 % between hospitals of diagnosis (p < 0.0001). Combined cytostatic regimens
(CAPOX/FOLFOX in 97 %) were prescribed in the majority of patients (63 %) and were associated with a higher
odds for additional treatment with bevacizumab than single-agent cytostatic regimens (OR 9.9, 95 % CI 5.51–18.00).
Median overall survival (OS) rates were 21.6 and 13.9 months with and without the addition of bevacizumab to
palliative systemic treatment respectively (p < 0.0001). The addition of bevacizumab to palliative chemotherapy was
associated with a reduced hazard ratio for death (HR 0.6, 95 % CI 0.45–0.73) after adjustment for patient- and tumor
characteristics and the prescribed chemotherapeutic regimen.
Conclusion: Bevacizumab is adopted as a therapeutic option for metachronous metastasized CRC mainly in addition
to first-line oxaliplatin-based regimens, and was associated with a reduced risk of death. The presence of inter-hospital
differences in the prescription of bevacizumab reflected important differences in attitude and policies in clinical
practice. Ongoing efforts should be made to further define the position of targeted agents in the treatment of
metastatic colorectal cancer.
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Background
Metastatic disease is a common manifestation in patients
with advanced colorectal cancer (CRC). Approximately
one fifth of patients presents with metastasized disease at
diagnosis [1–3] and 20 % of patients with initial M0 dis-
ease develops metachronous metastases [4].
Fluorouracil based palliative chemotherapy has been
the mainstay of treatment for many years. Over the
past decade, the systemic treatment of metastatic CRC
(mCRC) has changed considerably. The availability of
the cytostatic drugs irinotecan and oxaliplatin has im-
proved the prognosis of mCRC patients [5]. Moreover,
advances in the understanding of molecular oncology
have served for the development of targeted agents such
as the anti-vascular endothelial growth factor blocking
agent (VEGF-a) bevacizumab. Although the efficacy of
bevacizumab has been established in patients with mCRC
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[6], the role of bevacizumab in clinical practice remains a
topic of debate. Population-based data are useful in
reflecting community based practice. To date, no such
population-based figures of patients with metachronous
metastases are available. Therefore the aim of this study is
to provide population-based data on the use and effect on
overall survival of bevacizumab in the palliative treatment
of metachronous metastasized CRC in the Netherlands.
Methods
Patients and data
Data from the population-based Netherlands Cancer
Registry (NCR), more specifically from the Eindhoven
area, were used. The Eindhoven Cancer Registry (ECR)
collects data of all patients with newly diagnosed cancer
in a large part of the Southern Netherlands. The ECR
covers an area of approximately 2.4 million inhabitants,
six pathology departments, ten hospitals and two radio-
therapy institutions. Patient and tumor characteristics
are collected from medical records by specially trained
registry staff after notification by pathologists and med-
ical registration offices, resulting in high quality of the
data. The completeness of cancer registration is esti-
mated to exceed 95 %. In the ECR, primary tumors are
classified according to the TNM classification of Malig-
nant Tumors by the international Union Against Cancer
(UICC), 7th edition [7]. Additional data were retrospect-
ively collected on metachronous metastases for patients
diagnosed between 2003 and 2008 with stage I-III CRC.
Hospitals were asked to participate in the study by giving
permission to use their data from the ECR and by giving
permission for the retrospective registration of additional
data. All hospitals voluntarily participated.
Metachronous metastases were defined as distant me-
tastases of primary CRC in other organs, diagnosed at
least 3 months after CRC diagnosis. However, the majority
of metachronous metastases diagnoses (94 %) occurred at
least 6 months after CRC diagnosis. Patterns of metastatic
disease were determined based on the site of metastasis
according to the International Classification of Diseases
for Oncology (ICD-O), which could involve multiple lo-
calizations. Median time from primary diagnosis to data
collection was 5.3 years (range 1.5–8.8 years). All con-
secutive patients with metachronous metastases from
primary resected CRC were selected (n = 1010). Patients
diagnosed with metachronous metastases before 2005
(n = 100) were excluded as bevacizumab is registered
and recommended as a therapeutic option in addition
to first-line chemotherapy in the Netherlands since
2005 [8]. Subsequently, patients undergoing surgery for
metastases were excluded (n = 232), resulting in a study
population treated with palliative intent (n = 678) of
whom 361 received palliative chemotherapy (with or
without palliative procedures; bypass, anastomosis, stoma).
These latter patients were categorized into two treatment
groups according to the prescription of bevacizumab in
addition to palliative chemotherapy (Fig. 1). In the current
study, we focused on the first-line palliative treatment as
this is the indication for which bevacizumab is registered
in the Netherlands.
Fig. 1 An overview on the palliative systemic treatment of metachronous metastases for patients diagnosed between 2003 and 2008 with stage
I-III colorectal cancer in the south of the Netherlands
Razenberg et al. BMC Cancer  (2016) 16:110 Page 2 of 9
Statistical analysis
Variation in the prescription of bevacizumab between hos-
pitals of diagnosis in the ECR-region was assessed using a
χ2 test. Also, differences in patient and tumor characteris-
tics and the prescription of bevacizumab between chemo-
therapeutic regimens were tested by means of a χ2 test. To
discriminate independent predictors of treatment with
bevacizumab, a multivariable logistic regression model
was used. Adjustments were made for relevant patient
and tumor characteristics: gender, age, comorbidity at
time of CRC diagnosis, primary tumor localization,
adjuvant chemotherapy, time to metastases, period of
metastases diagnosis, number of metastases and the
prescribed first-line chemotherapeutic regimen. In
order to limit potential endogeneity bias due to the
population-based nature of the data, a propensity score
matched sample was created. Propensity scores were
determined with a logistic regression model in which
bevacizumab was the variable of interest and the inde-
pendent variables were factors potentially associated
with the use of bevacizumab (similar to variables taken
into account in the multivariable logistic regression
analysis). Patients were then matched within tight
bounds of the propensity scores (probability could vary
by no more than 1 %). Overall survival time was defined
as the time from diagnosis of the first metachronous
metastatic site to death or lost to follow-up. Patients still
alive at the end of follow-up (January 1st, 2014) and those
who emigrated were censored. Crude survival estimates
according to the prescription of bevacizumab were calcu-
lated with the Kaplan-Meier method and presented up to
48 months in both the total study population and the pro-
pensity score matched sample. Median survival (MS) was
presented in months and corresponding 95 % confidence
intervals (CIs). A log-rank test was carried out to evaluate
significant differences between survival curves. Multivari-
able Cox regression analyses were performed in both the
total study population and propensity score matched
sample to evaluate the independent effect of additional
bevacizumab on the risk of death. Adjustments were
made for the clinically relevant variables age, comorbid-
ity, localization of primary tumor, adjuvant chemother-
apy, time to metastases, period of metastases diagnosis,
number of metastases, prescribed first-line chemothera-
peutic regimen and the total number of systemic lines for
the treatment of metastases. All analyses were performed
with SAS/STAT® statistical software (SAS system 9.3; SAS
institute, Cary, NC).
Ethical considerations
In the Netherlands, the NCR and Dutch hospitals have a
formal agreement that all cancer patients are informed
about registration in the Cancer Registry and the possi-
bility to decline registration. According to the Dutch
law, all cancer patients are included in the NCR unless
the patient has objected to be registered. Therefore, con-
sent of the patient for this specific study was not
applicable.
The NCR retrospectively collects data from medical
records and is obligated to work according to laws in
which the privacy of patients and doctors is fixed in reg-
ulations; the law about protection of privacy and the law
“Geneeskundige BehandelOvereenkomst”. An independ-
ent Committee of Privacy reassures that the NCR works
compliant to these regulations. In the Netherlands,
retrospective studies with data collected from medical
charts do not fall under the scope of the Medical Re-
search Involving Human Subjects Act (‘Wet Medisch-
wetenschappelijk Onderzoek”) as patient integrity is not
violated in these studies. Therefore, this study was
exempted from further medical ethics review.
Results
Out of 5671 primary resected stage I-III CRC patients
diagnosed between 2003 and 2008, 1010 patients devel-
oped metachronous metastases (18 %). In total, 361
patients received first-line systemic therapy for the pal-
liative treatment of metachronous colorectal metasta-
ses. Palliative procedures including a diverting stoma,
bypass or anastomosis were performed in a minority of
the patients (n = 18,5 %). Bevacizumab was prescribed
in 51 % of the patients (n = 185), with proportions vary-
ing from 36 % to 80 % between the 10 hospitals in the
ECR region (p < 0.0001, Fig. 2). An overview of patient
and tumor characteristics according to the addition of
bevacizumab to first-line systemic therapy is shown in
Table 1.
Patient and tumor characteristics
Of the 361 patients treated with first-line systemic ther-
apy, 219 patients received combination chemotherapy
Fig. 2 Proportion of patients receiving first-line palliative chemotherapy
plus bevacizumab according to hospital of diagnosis (n= 361)
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(CAPOX/FOLFOX in 96 %) and 142 patients received
single-agent chemotherapy (capecitabine 74 %, irinote-
can 20 %). Patient and tumor characteristics of patients
treated with these chemotherapeutic regimens are shown
in Table 1. Patients receiving combination chemotherapy
were younger, had less comorbidities, were more often
diagnosed with rectal tumors and less often received prior
adjuvant chemotherapeutic treatment than patients receiv-
ing single-agent chemotherapy. Moreover, patients treated
with combination chemotherapy more frequently received
bevacizumab (n = 153, 70 %) than patients treated with
single-agent chemotherapy (n = 32, 23 %, p < 0.0001).
Table 1 Patient and tumor characteristics according to the addition of bevacizumab to first-line systemic therapy (n = 361)
N = 361 Without bevacizumab
(n = 176)
With bevacizumab
(n = 185)
Combination
chemotherapy (n = 219)
Single-agent
chemotherapy (n = 142)
N (%) N (%) P-value N (%) N (%) P-value
Gender 0.69 0.33
Male 75 (43) 72 (41) 126 (58) 89 (63)
Female 101 (57) 113 (59) 93 (42) 53 (37)
Age (years) <0.0001 <0.0001
< 60 36 (20) 57 (31) 71 (32) 24 (17)
60–75 91 (52) 111 (60) 128 (59) 72 (51)
≥ 75 49 (28) 17 (9) 20 (9) 46 (32)
Comorbidity <0.001 <0.01
No 50 (28) 81 (44) 38 (28) 91 (42)
1 comorbid condition 49 (28) 56 (30) 36 (26) 66 (30)
≥ 2 comorbid conditions 63 (36) 33 (18) 52 (36) 44 (20)
Unknown 14 (8) 15 (8) 14 (19) 18 (8)
Primary tumor localization 0.13
Rectum 68 (39) 85 (46) 107 (49) 47 (33) <0.01
Colon 108 (61) 100 (54) 112 (51) 95 (67)
Adjuvant chemotherapy 0.34 <0.01
No 103 (59) 100 (54) 137 (63) 67 (47)
Yes 73 (41) 85 (46) 82 (37) 75 (53)
Time to metastases (years) 0.12 0.59
< 1 year 57 (32) 43 (23) 57 (26) 42 (30)
1–2 years 56 (32) 71 (38) 82 (37) 46 (32)
≥ 2 years 63 (36) 71 (38) 80 (37) 54 (38)
Period of diagnosis metastases <0.01 0.81
2005–2006 70 (40) 41 (22) 69 (31) 42 (30)
2007–2008 57 (32) 78 (42) 83 (38) 52 (37)
2009–2011 49 (28) 66 (36) 67 (31) 48 (34)
Number of organs affected 0.29 0.39
1 organ 72 (41) 85 (46) 92 (42) 65 (46)
2 organs 69 (39) 59 (32) 83 (38) 44 (31)
≥ 3 organs 35 (20) 41 (22) 44 (20) 33 (23)
First-line chemotherapy <0.0001
Single agent chemotherapy 110 (63) 32 (27)
Combination chemotherapy 66 (37) 153 (83)
Bevacizumab <0.0001
Yes 153 (70) 32 (23)
No 66 (30) 110 (77)
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Predictors of treatment with bevacizumab
In multivariable regression analysis including adjustment
for the type of prescribed first-line chemotherapeutic
regimen, several factors were shown to influence the
probability to receive additional first-line bevacizumab
(Table 2). It was confirmed that patients treated with
combination chemotherapy were more likely to receive
bevacizumab than patients treated with single-agent
chemotherapy (OR 9.666, 95 % CI 5.43–17.05). More-
over, the odds for treatment with bevacizumab was
higher for patients diagnosed with metastases in a re-
cent time period than patients diagnosed with metasta-
ses shortly after the introduction of bevacizumab in
Dutch guidelines (2005–2006). The probability to receive
bevacizumab was lower for patients with ≥2 comorbidities
than patients without comorbidity (OR 0.4, 95 % CI 0.21–
0.81) No association was observed between age and the
use of bevacizumab. However, elderly patients (≥75 years)
were less likely to receive combination chemotherapy (OR
0.2, 95 % CI 0.11–0.30).
Survival analysis
As shown in Fig. 3, the addition of bevacizumab to
first-line palliative chemotherapy was associated with
an improved median overall survival, from 14 months
(95 % CI 11–16) to 22 months (95 % CI 19–24) (log
rank p < 0.0001). In the propensity score matched sam-
ple, including 60 patients (with bevacizumab n = 30,
without bevacizumab n = 30), comparable results were
found with a median overall survival of 13 months (95%CI
7.62–18.92) versus 25 months (95%CI 7.62–18.92) (log
rank p < 0.05). In multivariable analysis, the addition of
bevacizumab to palliative chemotherapy resulted in a re-
duced hazard ratio on death, in both the total study popu-
lation (HR 0.6, 95 % CI 0.45–0.73) and propensity score
matched sample (HR 0.3; 95 % CI 0.14-.079, Table 3).
After stratification for the prescribed first-line chemother-
apeutic regimen, the beneficial effect of the addition of
bevacizumab was observed in the subset of patients re-
ceiving combination chemotherapy (HR 0.6; 95 % CI
0.40–0.81), but not in patients treated with single-agent
chemotherapy (HR 0.9, 95 % CI 0.60–1.54).
Table 2 Proportion of patients treated with bevacizumab among
patients who received chemotherapy, and predictors of treatment
with bevacizumab in first line, adjusted for all factors listed (n= 361)
N = 361 N (%) OR 95 % CI
Gender
Male 72 (49) Ref
Female 113 (53) 1.3 0.79–2.16
Age (years)
< 60 57 (60) Ref
60–74 111 (56) 1.1 0.61–2.05
≥ 75 17 (26) 0.5 0.22–1.27
Comorbidity
No 81 (62) Ref
1 comorbid condition 56 (54) 0.8 0.42–1.45
≥ 2 comorbid conditions 33 (34) 0.4 0.21–0.81
Unknown 15 (48) 0.7 0.27–1.65
Primary tumor localization
Rectum 85 (55) Ref
Colon 100 (48) 0.9 0.37–2.26
Adjuvant chemotherapy
No 100 (49) Ref
Yes 85 (54) 1.7 0.98–2.96
Time to metastases (years)
< 1 year 43 (43) Ref
1–2 years 71 (55) 1.5 0.78–2.82
≥ 2 years 71 (53) 1.2 0.60–2.30
Period of diagnosis metastasis
2005–2006 41 (37) Ref
2007–2008 78 (58) 3.0 1.62–5.70
2009–2011 66 (57) 3.3 1.67–6.74
Number of organs affected
1 organ 85 (54) Ref
2 organs 59 (46) 0.5 0.29–0.91
≥ 3 organs 41 (53) 0.9 0.46–1.74
First-line chemotherapy
Single agent chemotherapy 32 (23) Ref
Combination chemotherapy 153 (70) 9.6 5.43–17.05
N; number of patients receiving bevacizumab in the first-line of
systemic treatment
%; percentage of patients receiving bevacizumab in the first-line of
systemic treatment
OR odds ratio, CI confidence interval
Bold data; P-value <0.05
Fig. 3 Overall survival according to the addition of bevacizumab to
first-line systemic therapy (n = 361)
Razenberg et al. BMC Cancer  (2016) 16:110 Page 5 of 9
Discussion
To our knowledge, this is the first study providing
population-based data on the use of bevacizumab in the
metachronous setting, which has been suggested to differ
from synchronous manifestation of disseminated disease
with respect to tumor biology and prognostics [9–11].
Table 3 Multivariable Cox regression analysis modelling the independent effect of additional bevacizumab on the risk of death,
adjusted for all factors listed
Total study population Propensity score matched sample
(N = 361) (N = 60)
HR 95 % CI P-value HR 95 % CI P-value
Age (years)
< 60 Ref Ref
60–74 1.0 0.76–1.38 0.86 1.8 1.82–4.13 0.15
≥ 75 1.3 0.87–1.90 0.21 0.8 0.20–3.53 0.80
Comorbidity
No Ref Ref
1 comorbid condition 0.9 0.69–1.22 0.56 1.1 0.40–2.86 0.88
≥ 2 comorbid conditions 0.8 0.54–1.04 0.08 1.0 0.34–3.01 1.07
Unknown 0.7 0.47–1.17 0.19 0.6 0.21–1.98 1.00
Primary tumor localization
Rectum Ref Ref
Colon 1.3 1.01–1.65 <0.05 0.6 0.21–1.98 0.35
Adjuvant chemotherapy
No Ref Ref
Yes 1.0 0.82–1.34 0.68 1.0 0.44–2.32 0.97
Time to metastases (years)
< 1 year Ref Ref
1–2 years 1.1 0.87–1.57 0.28 0.7 0.25–1.87 0.46
≥ 2 years 1.0 0.72–1.31 0.85 0.4 0.16–1.22 0.11
Period of diagnosis metastasis
2005–2006 Ref Ref
2007–2008 1.1 0.81–1.64 0.42 2.3 0.64–8.34 0.20
2009–2011 1.1 0.78–1.71 0.47 2.5 0.67–9.62 0.16
Number of organs affected
1 organ Ref Ref
2 organs 1.2 0.96–1.63 0.19 1.8 0.74–4.78 0.18
≥ 3 organs 1.6 1.12–2.21 <0.01 4.3 1.48–13.00 <0.01
First-line chemotherapy
Single agent chemotherapy Ref Ref
Combination chemotherapy 0.9 0.69–1.27 0.69 0.2 0.07–0.49 <0.001
Additional bevacizumab
No Ref
Yes 0.6 0.49–0.89 <0.01 0.3 0.14–0.79 <0.05
Number of systemic lines
1 line Ref
2 lines 0.6 0.44–0.84 <0.01 0.5 0.16–1.74 0.29
≥ 3 lines 0.4 0.31–0.58 <0.0001 0.3 0.13–0.72 <0.01
N number of patients, HR hazard ratio, CI confidence interval
Bold data; P-value <0.05
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Bevacizumab was prescribed in approximately half of the
patients with metachronous metastases receiving first-line
palliative treatment between 2005 and 2011 in the south-
ern part of the Netherlands, achieving a median overall
survival of 22 months. Prescription of bevacizumab varied
significantly between hospitals of diagnosis and depended
on the prescribed chemotherapeutic regimen.
The inter-hospital variation in the adoption of bevaci-
zumab as observed in our study may reflect differences
in policy and attitude towards the use of this anti-
angiogenic agent in daily practice [12]. Bevacizumab
was FDA-approved following the landmark publication
by Hurwitz et al in which a survival benefit was demon-
strated in patients treated with irinotecan, bolus fluoro-
uracil and leucovorin (IFL) [6]. However, by the time
bevacizumab was adopted in clinical practice, a shift to-
wards oxaliplatin-based chemotherapy had taken place
in the Netherlands [13–15]. Due to the initial absence
of efficacy data in addition to these oxaliplatin contain-
ing regimens and the controversial results that were re-
ported later on [16], the role of bevacizumab remained
a highly debated topic. Also, the recent introduction of
antibodies against epidermal growth factor receptors
(EGFR) [17] strengthened the debate, as the question
was raised which targeted agent should be preferred in
the first-line systemic treatment [18]. In order to pre-
vent an expanding gap between “believers” and “non-
believers” in the current era of evolving treatment op-
tions for mCRC, ongoing efforts are needed to establish
an evidence based opinion on the use of bevacizumab.
In line with the Dutch guidelines, the majority of pa-
tients with metachronous metastases received oxaliplatin-
based chemotherapy (CAPOX or FOLFOX) whereas
fewer patients were treated with single-agent chemother-
apy (mostly capecitabine). Elderly patients and patients
with multiple comorbidities were less often considered
candidates for treatment with oxaliplatin-based chemo-
therapy, reflecting the generally accepted opinion that
individual components of a systemic regimen should be
selected on a number of factors, including patient re-
lated factors such as age, performance status and co-
morbidity [19]. Moreover, we observed that adjuvant
chemotherapy influenced the choice of chemotherapy
for the treatment of metachronous metastases. If adjuvant
chemotherapy was prescribed, patients were less likely to
receive combination chemotherapy as palliative treatment.
This probably reflects the persistence of troublesome oxali-
platin induced polyneuropathy after adjuvant chemotherapy
[20]. Since 2004, adjuvant oxaliplatin-based chemotherapy
is considered the standard treatment schedule in the
Netherlands for high risk stage II and stage III colonic tu-
mors [21, 22]. For rectal tumors, however, adjuvant chemo-
therapy is generally not recommended, which probably
explains the relatively higher proportion of oxaliplatin-
based regimens for the treatment of metastases in this sub-
set of patients.
The likelihood of treatment with bevacizumab was
shown to depend strongly on the prescribed chemothera-
peutic regimen for the metastatic disease. If a patient was
considered a candidate for combination-chemotherapy,
bevacizumab was prescribed in approximately 70 % of the
cases. On the opposite, if single-agent chemotherapy was
prescribed, only 23 % of the patients received bevacizu-
mab. These findings are in line with results from observa-
tional cohort studies in the U.S. [13–15]. Of course, it
could be speculated that bevacizumab was prescribed in
combination with further lines of chemotherapy, as the
results from the CAIRO III study revealed equal results
for combined and sequential treatment chemotherapy
strategies [23]. However, very few patients included in the
current study received bevacizumab in further lines of
treatment (data not shown).
In accordance with observations from the current lit-
erature in which age has been identified as one of the
most important factors when deciding the type of ther-
apy for patients with mCRC [24, 25], we observed that
elderly patients (≥75 years) were less likely to receive
combination-chemotherapy than younger patients. How-
ever, advanced age did not influence the probability to
receive bevacizumab if adjustments were made for the
prescribed chemotherapeutic regimen. Thus, age influ-
enced primarily the choice of cytostatic backbone. This
observation reflects the lack of data on the benefit-risk ra-
tio of combination-chemotherapy regimens in older pa-
tients. It has been shown that the bevacizumab related
adverse events do not increase with age, except for arterial
thromboembolic events [26]. However, for this complica-
tion other patient related factors appeared to be stronger
predictive factors than age [26]. Bevacizumab should
therefore be considered a potential therapeutic option for
elderly patients with mCRC and age alone should not be
considered an absolute contraindication [27].
The addition of bevacizumab to first-line palliative
therapy was associated with a median overall survival of
22 months, which is consistent with reports from ob-
servational studies on mCRC from the period 2002–2007
[13–15]. Of course, this observed improvement in overall
survival with the addition of bevacizumab was biased by
the prescription of more potential cytostatic backbone
regimens in the presence of bevacizumab, and by patient
selection by the treating physician. Nevertheless, after
adjustment for important prognostic factors such as the
prescribed chemotherapeutic regimen, a reduced hazard
of death was observed in patients receiving additional bev-
acizumab. Moreover, results remained present in the pro-
pensity score matched sample, in which an effort is made
to limit potential endogeneity bias. After stratification for
the type of chemotherapy, the beneficial effect of
Razenberg et al. BMC Cancer  (2016) 16:110 Page 7 of 9
additional bevacizumab achieved significance only in the
subset of patients treated with combination-
chemotherapy, probably because patient numbers were
too small in the subset of single-agent backbone therapy.
Although these non-randomized observational data
should be interpreted with caution, together with the
demonstrated benefit of bevacizumab across chemother-
apy regimens in several RCTs [6, 16, 28–30] and observa-
tional studies [13–15], they strengthen the suggestion that
bevacizumab is likely to add activity to various chemother-
apy regimens with which it is combined.
Despite the accurate and concise patient registration,
use of the ECR also implies limitations to our data. No
data on relevant prognostic factors such as extent of
metastatic burden were available. Moreover, data on pa-
tient and tumor characteristics such as comorbidity are
registered by registration personnel approximately 6–9
months after primary tumor diagnosis. Therefore, it is
not possible to provide data on the specific comorbidi-
ties present at the time of treatment for metachronous
metastases.
Conclusions
In conclusion, in this population-based study it was re-
vealed that addition of bevacizumab to the first line
treatment of metachronous metastases of CRC is likely
to be an independent beneficial factor for overall survival
in patients receiving oxaliplatin containing chemother-
apy. Moreover, a significant inter-hospital difference in
the prescription of bevacizumab was found, reflecting
differences in attitude towards and policies in the use of
bevacizumab in clinical practice. Ongoing efforts should
be made to further define the position of targeted agents
in the treatment of metachronous metastases from CRC.
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